[The comparison of adverse reactions to anti-influenza vaccines of split-vision and surface antigens].
Identifieur interne : 000703 ( Main/Exploration ); précédent : 000702; suivant : 000704[The comparison of adverse reactions to anti-influenza vaccines of split-vision and surface antigens].
Auteurs : D. Bautista Rentero ; J M Tenías Burillo ; A. Sabater Pons ; B. Pérez Bermúdez ; V. Zan N ViguerSource :
- Revista espanola de salud publica [ 1135-5727 ]
Descripteurs français
- KwdFr :
- Adulte (MeSH), Adulte d'âge moyen (MeSH), Espagne (MeSH), Femelle (MeSH), Grippe humaine (immunologie), Grippe humaine (prévention et contrôle), Humains (MeSH), Mâle (MeSH), Personnel de santé (MeSH), Services de médecine préventive (MeSH), Sujet âgé (MeSH), Vaccination (MeSH), Vaccins antigrippaux (effets indésirables).
- MESH :
- effets indésirables : Vaccins antigrippaux.
- immunologie : Grippe humaine.
- prévention et contrôle : Grippe humaine.
- Adulte, Adulte d'âge moyen, Espagne, Femelle, Humains, Mâle, Personnel de santé, Services de médecine préventive, Sujet âgé, Vaccination.
- Wicri :
- geographic : Espagne.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Influenza Vaccines.
- geographic : Spain.
- immunology : Influenza, Human.
- prevention & control : Influenza, Human.
- Adult, Aged, Female, Health Personnel, Humans, Male, Middle Aged, Preventive Health Services, Vaccination.
Abstract
BACKGROUND
Fear of adverse reactions is one of the reasons why influenza immunization programs for hospital workers have not met wide acceptance. We conducted a study in order to compare the frequency of adverse reactions following administration of standard split-virion (VVF) and subunit-virion (VAS) influenza vaccines, mostly among hospital personnel.
METHODS
Trial with volunteers who were systematically assigned to receive one of the vaccines, alternating every ten participants, during the influenza inmunization campaing 1994-95. The adverse effects were recorded by telephone interview 10 days after vaccination.
RESULTS
Out the 182 subjects recruited, 163 were included in the study, of whom 100 received VAS and 63, VVF. Almost 13% of the participants reported any adverse effects with no significant difference between both groups (VAS: 11% and VVF: 15.6%, p = 0.38). There were also no significant differences relating to systemic and local reactions, separately. The subjects who had adverse reactions to previous influenza vaccination showed more frecuent systemic reactions (25% vs. 7.5%, p = 0.04) in a significant way.
CONCLUSIONS
Both vaccines have been proved to be very safe, only causing adverse reactions in a small proportion and very mild in every case. The VAS presents a frequency of adverse effects similar to that of VVF, in spite of containing only surface antigens. It's likely that a certain hypersensitivity to influenza vaccine exists in some people, specially to the split-virion one.
PubMed: 8789358
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[The comparison of adverse reactions to anti-influenza vaccines of split-vision and surface antigens].</title><author><name sortKey="Bautista Rentero, D" sort="Bautista Rentero, D" uniqKey="Bautista Rentero D" first="D" last="Bautista Rentero">D. Bautista Rentero</name><affiliation><nlm:affiliation>Servicio de Medicina Preventiva y Salud Pública, Hospital Dr. Peset, Valencia.</nlm:affiliation><wicri:noCountry code="subField">Valencia</wicri:noCountry></affiliation></author><author><name sortKey="Tenias Burillo, J M" sort="Tenias Burillo, J M" uniqKey="Tenias Burillo J" first="J M" last="Tenías Burillo">J M Tenías Burillo</name></author><author><name sortKey="Sabater Pons, A" sort="Sabater Pons, A" uniqKey="Sabater Pons A" first="A" last="Sabater Pons">A. Sabater Pons</name></author><author><name sortKey="Perez Bermudez, B" sort="Perez Bermudez, B" uniqKey="Perez Bermudez B" first="B" last="Pérez Bermúdez">B. Pérez Bermúdez</name></author><author><name sortKey="Zan N Viguer, V" sort="Zan N Viguer, V" uniqKey="Zan N Viguer V" first="V" last="Zan N Viguer">V. Zan N Viguer</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1995">1995 Nov-Dec</date><idno type="RBID">pubmed:8789358</idno><idno type="pmid">8789358</idno><idno type="wicri:Area/Main/Corpus">00703</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">00703</idno><idno type="wicri:Area/Main/Curation">000703</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000703</idno><idno type="wicri:Area/Main/Exploration">000703</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[The comparison of adverse reactions to anti-influenza vaccines of split-vision and surface antigens].</title><author><name sortKey="Bautista Rentero, D" sort="Bautista Rentero, D" uniqKey="Bautista Rentero D" first="D" last="Bautista Rentero">D. Bautista Rentero</name><affiliation><nlm:affiliation>Servicio de Medicina Preventiva y Salud Pública, Hospital Dr. Peset, Valencia.</nlm:affiliation><wicri:noCountry code="subField">Valencia</wicri:noCountry></affiliation></author><author><name sortKey="Tenias Burillo, J M" sort="Tenias Burillo, J M" uniqKey="Tenias Burillo J" first="J M" last="Tenías Burillo">J M Tenías Burillo</name></author><author><name sortKey="Sabater Pons, A" sort="Sabater Pons, A" uniqKey="Sabater Pons A" first="A" last="Sabater Pons">A. Sabater Pons</name></author><author><name sortKey="Perez Bermudez, B" sort="Perez Bermudez, B" uniqKey="Perez Bermudez B" first="B" last="Pérez Bermúdez">B. Pérez Bermúdez</name></author><author><name sortKey="Zan N Viguer, V" sort="Zan N Viguer, V" uniqKey="Zan N Viguer V" first="V" last="Zan N Viguer">V. Zan N Viguer</name></author></analytic><series><title level="j">Revista espanola de salud publica</title><idno type="ISSN">1135-5727</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Female (MeSH)</term><term>Health Personnel (MeSH)</term><term>Humans (MeSH)</term><term>Influenza Vaccines (adverse effects)</term><term>Influenza, Human (immunology)</term><term>Influenza, Human (prevention & control)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Preventive Health Services (MeSH)</term><term>Spain (MeSH)</term><term>Vaccination (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Espagne (MeSH)</term><term>Femelle (MeSH)</term><term>Grippe humaine (immunologie)</term><term>Grippe humaine (prévention et contrôle)</term><term>Humains (MeSH)</term><term>Mâle (MeSH)</term><term>Personnel de santé (MeSH)</term><term>Services de médecine préventive (MeSH)</term><term>Sujet âgé (MeSH)</term><term>Vaccination (MeSH)</term><term>Vaccins antigrippaux (effets indésirables)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Spain</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Health Personnel</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Preventive Health Services</term><term>Vaccination</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Espagne</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Personnel de santé</term><term>Services de médecine préventive</term><term>Sujet âgé</term><term>Vaccination</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Espagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>Fear of adverse reactions is one of the reasons why influenza immunization programs for hospital workers have not met wide acceptance. We conducted a study in order to compare the frequency of adverse reactions following administration of standard split-virion (VVF) and subunit-virion (VAS) influenza vaccines, mostly among hospital personnel.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>Trial with volunteers who were systematically assigned to receive one of the vaccines, alternating every ten participants, during the influenza inmunization campaing 1994-95. The adverse effects were recorded by telephone interview 10 days after vaccination.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Out the 182 subjects recruited, 163 were included in the study, of whom 100 received VAS and 63, VVF. Almost 13% of the participants reported any adverse effects with no significant difference between both groups (VAS: 11% and VVF: 15.6%, p = 0.38). There were also no significant differences relating to systemic and local reactions, separately. The subjects who had adverse reactions to previous influenza vaccination showed more frecuent systemic reactions (25% vs. 7.5%, p = 0.04) in a significant way.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>Both vaccines have been proved to be very safe, only causing adverse reactions in a small proportion and very mild in every case. The VAS presents a frequency of adverse effects similar to that of VVF, in spite of containing only surface antigens. It's likely that a certain hypersensitivity to influenza vaccine exists in some people, specially to the split-virion one.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8789358</PMID><DateCompleted><Year>1996</Year><Month>10</Month><Day>17</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1135-5727</ISSN><JournalIssue CitedMedium="Print"><Volume>69</Volume><Issue>6</Issue><PubDate><MedlineDate>1995 Nov-Dec</MedlineDate></PubDate></JournalIssue><Title>Revista espanola de salud publica</Title><ISOAbbreviation>Rev. Esp. Salud Publica</ISOAbbreviation></Journal><ArticleTitle>[The comparison of adverse reactions to anti-influenza vaccines of split-vision and surface antigens].</ArticleTitle><Pagination><MedlinePgn>463-8</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Fear of adverse reactions is one of the reasons why influenza immunization programs for hospital workers have not met wide acceptance. We conducted a study in order to compare the frequency of adverse reactions following administration of standard split-virion (VVF) and subunit-virion (VAS) influenza vaccines, mostly among hospital personnel.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Trial with volunteers who were systematically assigned to receive one of the vaccines, alternating every ten participants, during the influenza inmunization campaing 1994-95. The adverse effects were recorded by telephone interview 10 days after vaccination.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Out the 182 subjects recruited, 163 were included in the study, of whom 100 received VAS and 63, VVF. Almost 13% of the participants reported any adverse effects with no significant difference between both groups (VAS: 11% and VVF: 15.6%, p = 0.38). There were also no significant differences relating to systemic and local reactions, separately. The subjects who had adverse reactions to previous influenza vaccination showed more frecuent systemic reactions (25% vs. 7.5%, p = 0.04) in a significant way.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Both vaccines have been proved to be very safe, only causing adverse reactions in a small proportion and very mild in every case. The VAS presents a frequency of adverse effects similar to that of VVF, in spite of containing only surface antigens. It's likely that a certain hypersensitivity to influenza vaccine exists in some people, specially to the split-virion one.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bautista Rentero</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Preventiva y Salud Pública, Hospital Dr. Peset, Valencia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tenías Burillo</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Sabater Pons</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Pérez Bermúdez</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Zanón Viguer</LastName><ForeName>V</ForeName><Initials>V</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Comparación de las reacciones adversas a las vacunas antigripales de virus fraccionados y de antígenos de superficie.</VernacularTitle></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Esp Salud Publica</MedlineTA><NlmUniqueID>9600212</NlmUniqueID><ISSNLinking>1135-5727</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006282" MajorTopicYN="N">Health Personnel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011314" MajorTopicYN="N">Preventive Health Services</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="Y">Vaccination</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1995</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1995</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1995</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8789358</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list></list><tree><noCountry><name sortKey="Bautista Rentero, D" sort="Bautista Rentero, D" uniqKey="Bautista Rentero D" first="D" last="Bautista Rentero">D. Bautista Rentero</name><name sortKey="Perez Bermudez, B" sort="Perez Bermudez, B" uniqKey="Perez Bermudez B" first="B" last="Pérez Bermúdez">B. Pérez Bermúdez</name><name sortKey="Sabater Pons, A" sort="Sabater Pons, A" uniqKey="Sabater Pons A" first="A" last="Sabater Pons">A. Sabater Pons</name><name sortKey="Tenias Burillo, J M" sort="Tenias Burillo, J M" uniqKey="Tenias Burillo J" first="J M" last="Tenías Burillo">J M Tenías Burillo</name><name sortKey="Zan N Viguer, V" sort="Zan N Viguer, V" uniqKey="Zan N Viguer V" first="V" last="Zan N Viguer">V. Zan N Viguer</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeEspagneV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000703 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000703 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeEspagneV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:8789358
|texte= [The comparison of adverse reactions to anti-influenza vaccines of split-vision and surface antigens].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:8789358" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeEspagneV1
| This area was generated with Dilib version V0.6.37. |  |